The data is encouraging: For the 325 cases treated with fecal transplants worldwide, almost 90 percent reported no relapse of C. difficile and no side effects. However, no randomized control trials have been done to test the treatment’s efficacy. All studies up to this point have been observational.
Related Articles on Gastroenterology:
Study: Virtual Colonoscopy Increases Colon Cancer Screening Rates
Study: American Ginseng Prevents Colon Cancer
Study: Same-Day Bowel Cleansing Regimen Superior to Split-Dose Regimen for Afternoon Colonoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
